glp-1 chronic kidney disease and the kidney: from physiology to pharmacology and outcomes in diabetes Glucagon-like peptide 1(GLP-1) receptor agonists

Among non-prescription approaches, though, oral l-carnitine stands out for having multiple human randomized trials showing consistent, modest benefits

Although studies on the relationship between HO-1 and macrophages in diabetes or its complications are limited, the mechanisms by which macrophages maintain the microenvironment stability of the body and HO-1s excellent antioxidant and anti-inflammatory properties suggest that targeting HO-1 with macrophages may be a treatment choice for diabetes (Fig

Obesity is associated with increased risk of Crohns disease, but not ulcerative colitis: a pooled analysis of five prospective cohort studies

Andreadis P, et al

10.1097/JTO.0b013e3181ba2f1d J